20 November 2007
INNOVAX™, the new innovative family of vaccines to aid in the prevention of very virulent Mareks Disease, Newcastle Disease and Infectious Laryngotracheitis (ILT), were launched successfully at the American Veterinary Medicine Association (AVMA) in Washington D.C., in July.
Intervet Inc. received a USDA license for INNOVAX-ND-SB and INNOVAX-ILT in the second quarter of this year. These vaccines are licensed to aid in the prevention of very virulent Mareks Disease and Newcastle Disease and virulent Mareks Disease and ILT, respectively. Both utilize the Hvt virus as a vector for additional viral agents. INNOVAX-ND-SB is the first recombinant vaccine for protection against very virulent Marek’s Disease and Newcastle Disease viruses for the vaccination of 18-day-old chick embryos.
With current R&D programmes, the INNOVAX family will be expanded over several years.
INNOVAX will be the main focus for Intervet at the International Poultry Expo (IPE) 2008, in Atlanta USA in January 2008.
